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j ourna l homepage: www.eb iomed ic ine.comEditorial2014: A Year of Breakthroughs for Translational Science2014 has been a remarkable year of scientiﬁc achievements, from
advances in our understanding of molecular pathways of human dis-
eases to the development of new interventional tools to tackle them.
Here, we highlight some promising initiatives and success stories from
the past year with clear translational relevance. The list is by no
means exhaustive but hopefully it provides a perspective on some of
the achievements that are good examples of the types of research
EBioMedicine aims to foster.
Although not an entirely new concept, a powerful new ap-
proach called CRISPR has been catapulted to center stage this
year as a means of highly speciﬁc gene targeting and modiﬁca-
tion. Clustered regularly interspaced short palindromic repeats
(CRISPR) are sequences naturally found in bacterial DNA that
work with CRISPR-associated (Cas) nucleases and guide RNAs
to protect the bacterial genomes from attacks by targeting spe-
ciﬁc sequences detected in invading bacteriophages. Proof-of-
principle research has emerged recently, which harnesses the
high sequence speciﬁcity of the system to cure genetic disor-
ders in animal models as well as creating disease-free stem
cells from affected patients. CRISPR also allows the creation of
mouse models with speciﬁc gene mutations for research pur-
poses within much shorter timeframes than existing methods.
Earlier this year, it was reported that the CRISPR-Cas system
has successfully been applied as a tool for performing efﬁcient
and highly speciﬁc genome-wide screening in human cells,
and vast improvements have been made in 2014 on increasing
target speciﬁcity, which opens up limitless possibilities for in-
terrogating gene function relevant to human health and
diseases.
Regenerative medicine and stem cell research have also seen multi-
ple advances and improvements in 2014. Stem cell therapies have
entered human clinical trials for diabetes, multiple sclerosis, andmacu-
lar degeneration, and this year we saw the ﬁrst demonstration that
human embryonic stem cells can have real-life therapeutic beneﬁt in re-
storing vision in a small cohort of legally blind patients. Achievements
have also been made in the research of neurodegenerative diseases
such as early-onset Alzheimer's and Parkinson's diseases, where the
growth of patient-derived stem cells in vitro will facilitate genetic
modeling of these diseases. These “in a dish”models of neurodegenera-
tive disordersmay also be used to screen and develop targeted therapies,
which should speed up the translational process toward beneﬁting real
patients.
This year, the United States Food and Drug Administration (FDA)
approved the ﬁrst monoclonal antibody against programmed death
protein 1 (PD-1)– pembrolizumab – for unresectable ormetastaticmel-
anoma. Based on early basic research regarding the role of PD-1 in thehttp://dx.doi.org/10.1016/j.ebiom.2014.11.016
2352-3964/© 2014 Published by Elsevier B.V.negative regulation of T-cell responses (which can render them ineffec-
tive in an anti-tumor response), research efforts have been focused on
blocking the interaction of PD-1 with its two ligands PD-L1 and PD-L2,
primarily for cancer treatment but also for other immunotherapeutic
applications. Pembrolizumab is also currently under expedited FDA re-
view as a breakthrough therapy for advanced non-small-cell lung can-
cer, and in clinical trials for several other cancers. Another anti-PD-1
monoclonal antibody under authority review for advanced non-small-
cell lung cancer and melanoma is nivolumab, which is also going
through numerous clinical trials for various other cancers including
renal cell carcinoma and head and neck cancer. Agents targeting the in-
teractions between PD-1 and its ligands are anticipated to be one of the
most valuable therapeutics in the next few years, and two decades of la-
borious basic and clinical research on the PD-1 pathway have ﬁnally
come to fruition.
2014 also welcomed two new once-weekly, long-acting glucagon-
like peptide 1 (GLP-1) receptor agonists for type 2 diabetes mellitus –
albiglutide and dulaglutide – following the success of once-weekly
exenatide. These drugs activate GLP-1 receptors expressed in many
tissues, including the pancreas and brain, and lower blood sugar concen-
trations by promoting glucose-dependent insulin release from pancreat-
ic beta cells and by slowing glucose absorption into the bloodstream. The
once-weekly regimen is expected to improve treatment compliance
compared with other daily regimens such as once-daily liraglutide and
twice-daily exenatide. Since the ﬁrst demonstration of GLP-1 receptor
cloning and functional expression 20 years ago, enormous research ef-
forts have been focused on developing GLP-1 receptor agonists to treat
diabetes, resulting in ﬁrst-in-human proof-of-concept studies in the
early 2000s. GLP-1 receptor agonists are yet another example of translat-
ing decades of research activity into interventional tools that beneﬁt
human health.
A new standard of care for the treatment of chronic hepatitis C virus
(HCV) infection has also been realized this year. HCV is amajor healthcare
burden, even in developed countries, with millions of newly infected
cases each year worldwide. The addition of sofosbuvir (a ﬁrst-in-class
HCVNS5B polymerase inhibitor), and its combinationwith theNS5A pro-
tein inhibitor ledipasvir, to the existing standard treatment of interferon
and ribavirin have greatly improved HCV treatment choices, and for the
ﬁrst time certain groups of chronic hepatitis C patients can beneﬁt from
anentirely oral, tablet-based therapywithout the needof interferon injec-
tion. The new ﬁxed-dose sofosbuvir/ledipasvir combination is formulated
in a single tablet, to be taken orally once a day, and can allow shorter
treatment durations compared with interferon/ribavirin treatment. The
sustained viral response rates were as high as 99% in some treatment
arms, and the addition of ribavirin to this new sofosbuvir/ledipasvir com-
bination did not improve response rates.
92 EditorialAll told, 2014has been a great year for translational research, andwe
congratulate those basic and clinical researchers whose achievements
have brought us closer to addressing long-standing challenges to
human health. These achievements illustrate that continuous and persis-
tent efforts to understand molecular mechanisms of human diseases andto develop innovative interventions can perfectly align with unmet med-
ical needs in human healthcare, and with the mission of EBioMedicine to
help communicate those needs by translating science to improve health.
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